[1] Clinicaltrials.gov, “Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above”. Available at: https://clinicaltrials.gov/study/NCT04886596 - last accessed: September 2024 [2] National Institute of Allergy and Infectious Diseases, ...
update on interventions for preventing respiratory syncytial virus (RSV) and its complications, highlighting recent advancements, including two vaccines for adults aged 60 and older, a monoclonal antibody for infants and high-risk children, and a maternal vaccine to prevent RSV infection in newbo...
Risks of RSV in Older Adults With Chronic Conditions RSV mostly affects children under 2, but it can be serious in adults over 65 who are immunocompromised or have chronic conditions. Here’s why. “No vaccine is 100 percent effective. An 80 percent vaccine effectiveness rate is quite impressi...
Older adults aren't the only group impacted by RSV. Very young children have been at the center of this winter's unusually severe RSV surge, which is now seeingcasesclimbing down from a steep peak. Pfizer also has amaternal vaccinein the race, which would be given to parents-to-be in ...
EP: 2.Non-adjuvant RSV Vaccine in Older Adults EP: 3.RSV Vaccine Efficacy in Pregnancy EP: 4.Who Not to Vaccinate Against RSV EP: 5.RSV Vaccine Administration Timing and Errors EP: 6.Role of the Pharmacist in Vaccinating Against RSV EP: 7.What is RSV? EP: 8.Lasting Impacts of ...
Adults who are at the highest risk for severe illness from RSV include adults with chronic heart or lung disease, adults with weakened immune systems, older adults, and adults living in nursing homes or long-term care facilities, according to the statement. The CDC estimates that RSV causes ap...
Approximately 1 in 10 adults aged ≥60 years received an RSV vaccination during the first season of vaccine availability, with relatively low uptake observed across ages and evaluated risk factors. Previous research has estimated that nearly half of older adults have a diagnosed risk factor for ...
The U.S. Food and Drug Administration on Wednesday approved the first RSV vaccine in the U.S. Scientists have been trying to develop an RSV vaccine for decades after previous high-profile attempts failed. The vaccine, made by the pharmaceutical company GSK, is for older adults. Pfizer and ...
Moderna’s experimental vaccine for respiratory syncytial virus (RSV) effectively prevented symptoms of disease in older adults in a large clinical trial, the companyannouncedTuesday. RSVis a common respiratory virus that usually causes mild, cold-like symptoms. But, particularly among young...
Grannis and colleagues used a test-negative study designed to compare the effectiveness of the RSV vaccine in adults aged 60 years or older admitted to a hospital or who had an ED visit for an RSV-like illness between Oct. 1, 2023, and March 31, 2024. The analysi...